ESR1 and breast cancer: Although targeting ER has been one of the most successful approaches in cancer therapy, such as breast cancer, combined treatment with an IGF-IR tyrosine kinase inhibitor (NVPAEW541) has been shown to exhibit synergism in inhibiting proliferation and inducing apoptosis in breast cancer cells [27]–[28].